Analysts' average 12-month price target for Summit Therapeutics is $27.
Get informed when a big investor buys or sells
+ Follow$17.12
6 analysts in the last 4 months
High: $38 | Low: $11.9
No recommendations in the last 4 months.
Summit Therapeutics posts a target price of $27. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.
A target price of $27 for SMMT means covering analysts, on average, see the stock 56.6% upside of $17.12 over about 12 months. Dig into who set the high and low targets and how recently they updated — freshness matters as much as the average itself.
Context for SMMT's target price usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; Summit Therapeutics's other metric pages and overview cover the third.